Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 23

Showing 23 citing articles:

Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment
Yue Qiu, Guimei Lu, Na Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
Jiao Wang, Chengyu Liu, Rong‐Hua Hu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Colony-stimulating factor 3 and its receptor promote leukocyte immunoglobulin-like receptor B2 expression and ligands in gastric cancer
Long Wang, Qi Wu, Z. Zhang, et al.
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 2
Closed Access
Tumor-derived extracellular vesicle PD-1 promotes tumor immune evasion via disruption of peripheral T cell homeostasis
Xiaodong Wang, Xiaohui Yang, Chang Huang, et al.
Cancer Letters (2025), pp. 217486-217486
Closed Access
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
Ke Wang, Chuangjie Zheng, Xinrong Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors
Fei Du, Guojun Wang, Qian Dai, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model
Hiroyuki Inoue, Takayuki Hamasaki, Kazuhiko Inoue, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Immune checkpoints regulate acute myeloid leukemia stem cells
C. Bachmann, Adrian F. Ochsenbein
Leukemia (2025)
Open Access
Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
Neha Sharma, Rupa Mazumder, Pallavi Rai, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 3
Closed Access | Times Cited: 3
Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes
Ting Li, Shichen Sun, Yubing Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: Inhibiting metastasis and reducing cardiotoxicity
Dandan Li, Yu Yao, Kun Wang, et al.
Biomaterials Advances (2024) Vol. 167, pp. 214114-214114
Closed Access | Times Cited: 2
PD-1 expression on tumor cells: a new target for cancer therapy
Mari Tone, Kota Iwahori
Translational Lung Cancer Research (2024) Vol. 13, Iss. 1, pp. 186-189
Open Access | Times Cited: 1
Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly
Mei Luo, Jiangfan Yu, Rui Tang
Journal of Neuro-Oncology (2024) Vol. 167, Iss. 3, pp. 415-425
Closed Access | Times Cited: 1
Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD‐1 by NGLY1
Dexuan Wu, Zhen Wu, Han Yao, et al.
FEBS Letters (2024) Vol. 598, Iss. 12, pp. 1543-1553
Closed Access | Times Cited: 1
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
Annapaola Montagner, Andrea Arleo, Fabrizia Suzzi, et al.
Biomolecules (2024) Vol. 14, Iss. 12, pp. 1581-1581
Open Access | Times Cited: 1
Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor
Hailang Yang, Li Ma, Wen Deng, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma
Heba A. Sahyon, Nadaa S. Alharbi, Zummar Asad, et al.
Children (2024) Vol. 11, Iss. 9, pp. 1035-1035
Open Access
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
Dayang Wang, Jiubing Zhang, Chaojie Bu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 10
Open Access
PD1-Targeted Transgene Delivery to Treg Cells
V. A. Zhuchkov, Yulia Evgenyevna Kravchenko, Elena I. Frolova, et al.
Viruses (2024) Vol. 16, Iss. 12, pp. 1940-1940
Open Access
Emerging Strategies for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Combining Immune Checkpoint Inhibitors with VEGF Inhibitors
Young Joo Park
Clinical Thyroidology (2024) Vol. 36, Iss. 10, pp. 377-380
Closed Access
Page 1

Scroll to top